Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

New immunotherapy yields long-lasting responses in some patients with advanced...

Dr Mark Middleton - University of Oxford, Oxford, UK

New immunotherapy yields long-lasting responses in some patients with advanced melanoma ( Dr Mark Middleton - University of Oxford, Oxford, UK )

What are the objectives for CART-meso immunotherapy?

Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA

What are the objectives for CART-meso immunotherapy? ( Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )

ecancermedicalscience editor's choice for April 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for April 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Positive results in phase II study of copanlisib treating NHL and CLL

Dr George Follows - Cambridge University Hospitals NHS Foundation Trust...

Positive results in phase II study of copanlisib treating NHL and CLL ( Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Inside cancer - public lecture

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

Inside cancer - public lecture ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Investigational immunotherapy drug combo safe with early signs of effectiveness...

Dr David Bajor - University of Pennsylvania, Philadelphia, USA

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma ( Dr David Bajor - University of Pennsylvania, Philadelphia, USA )

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Dr Evan Alley - University of Pennsylvania, Philadelphia, USA

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )

Chk1 inhibition combined with standard dose gemcitabine may be safe and...

Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )

Developing treatments for indolent non hodgkin lymphoma

Dr Andrew Davies and Dr Paul Fields

Developing treatments for indolent non hodgkin lymphoma ( Dr Andrew Davies and Dr Paul Fields )

Updated results on phase III CLL trial shows 90% response rate using ibrutinib

Dr Claire Dearden - Royal Marsden Hospital, London, UK

Updated results on phase III CLL trial shows 90% response rate using ibrutinib ( Dr Claire Dearden - Royal Marsden Hospital, London, UK )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

More from ecancer